Combined chemotherapy and allogeneic human Vγ9Vδ2 T lymphocyte-immunotherapies efficiently control the development of human epithelial ovarian cancer cells in vivo

Epithelial ovarian cancer (EOC) represents 5% of human gynecologic cancers in the world, is heterogeneous and highly invasive with a dismal prognosis (5 year-survival rate <35%). Diagnosis of EOC is frequently made at advanced stages and, despite aggressive treatments combining surgery and chemother...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Noémie Joalland, Laura Lafrance, Thibauld Oullier, Séverine Marionneau-Lambot, Delphine Loussouarn, Ulrich Jarry, Emmanuel Scotet
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2019-11-01
coleção:	OncoImmunology
Assuntos:	human vγ9vδ2 t lymphocytes zoledronate chemotherapy immunotherapy epithelial ovarian cancer orthotopic xenograft mouse model
Acesso em linha:	http://dx.doi.org/10.1080/2162402X.2019.1649971
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!